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Cystic Fibrosis is the most common inherited genetic respiratory disorder in the Western World. Hypovitaminosis D is almost
universal in CF patients, likely due to a combination of inadequate absorption, impaired metabolism, and lack of sun exposure.
Inadequate levels are associated with the high prevalence of bone disease or osteoporosis in CF patients, which is associated with
increased morbidity including fractures, kyphosis, and worsening pulmonary status. Treatment goals include regular monitoring
25 hydroxyvitamin D (25OHD) levels with aggressive treatment for those with levels <75nmol/L (<30ng/mL). More research is
needed to determine optimal supplementation goals and strategies.
1. CysticFibrosis
With an estimated incidence of 1 per 3000 live births cystic
ﬁbrosis (CF) is the most common inherited respiratory dis-
ease in the western world [1, 2]. CF is caused by dysfunction
of the CF transmembrane conductance regulator (CFTR),
a chloride channel present on epithelial cells. Thus, CFTR
mutations aﬀect the respiratory, gastrointestinal, hepato-
biliary, and reproductive systems as well as sweat glands.
Most patients with CF succumb to respiratory failure from
chronic pulmonary infection. Environmental, nutritional,
and socioeconomic factors as well as modiﬁer genes may
aﬀect the clinical manifestations of the disorder. Although a
single gene deletion, F508del, is responsible for a majority
of the mutations causing CF worldwide, more than 1600
m u t a t i o n si nC F T Rh a v eb e e nd e s c r i b e d[ 3]. While there is
great geographic and ethnic variation in the frequency of the
disorder, CF remains predominantly a disease in Caucasians.
The mean survival age in CF patients continues to improve
from 2 in the 1950s to 37 years currently with roughly half
of all CF individuals being of adult age. Survival is closely
associated with both pulmonary and nutritional status
[4–7].
2. Diagnosisof VitaminDDeﬁciency
Like with non-CF individuals, the 25 hydroxyvitamin D
(25OHD) level determines the degree of vitamin D insuﬃ-
ciency and, following data published outside CF, a 25OHD
level <75nmol/L (30ng/mL) is considered insuﬃcient. All
CF patients should have vitamin D levels checked annually,
ideally by high-performance liquid chromatography (HPLC)
mass spectrometry test. Serum concentrations of 1–25
dihydroxyvitamin D have little impact on the management
of vitamin D problems in CF. These levels are often normal
or elevated in the setting of vitamin D deﬁciency due to
increased activity of renal 1-hydroxylase under the inﬂuence
of elevated PTH [8]. As in the general population, serum
25OHD levels may display variability based on the time of
year and latitude and should be checked in late fall or winter
to determine the degree of deﬁciency.
3. Magnitudeand Causesof
VitaminDDeﬁciency inCF
CF represents the “perfect storm” for vitamin D deﬁciency.
More than 20 studies have documented low levels of 25OHD2 International Journal of Endocrinology
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Figure 1: Causes of Vitamin D insuﬃciency in CF Patients [11].
from around the world and at many diﬀerent latitudes.
In recent studies from large CF Centers, >90% of patients
have 25OHD levels < 75nmol/L (30ng/mL) [9, 10]. Table 1
summarizes many of the documented 25OHD levels over the
last few decades. These data suggest a trend toward higher
25OHD levels over recent years (especially among larger
studies), which likely reﬂects increased attention to 25OHD
levels by most large CF centers. The continued presence of
low 25OHD emphasizes the continued inadequate supple-
mentation despite increased awareness.
The multifactorial etiology of low vitamin D levels in
CF patients is illustrated in Figure 1. Despite routine oral
supplementation, intake of vitamin D is often inadequate
[10]. Ingested vitamin D is often not absorbed due to
exocrine pancreatic insuﬃciency, present in 85% to 90% of
individuals with CF [12]. Exocrine pancreatic insuﬃciency
causes intestinal malabsorption of all fat soluble vitamins.
Cystic ﬁbrosis patients have impaired absorption of vitamin
D from both plant sources (vitamin D2) and animal
sources (vitamin D3) [8]. Figure 2 obtained from Lark et al.
illustrates the decreased absorption from a single 2500ug
dose of vitamin D2 in CF patients despite pancreatic enzyme
supplementation. Both decreased serum levels of vitamin D2
and 25OHD were noted [13]. With chronic supplementa-
tion, however, 25OHD levels do show some improvement
with pancreatic enzyme and vitamin supplementation [14].
In addition to vitamin D malabsorption, CF patients
exhibit impaired hepatic hydroxylation, which may aﬀect
metabolism of manufactured vitamin D and vitamin D
absorbed through the gastrointestinal tract [15–25]. The
kinetics of vitamin D metabolism have not been studied in
CF in detail (i.e., tracer studies), but indirect data suggest
thattheremaybeacceleratedexcretionofvitaminD,possibly
through enterohepatic dumping, before exposure to the
hepatic 25-hydroxylase enzyme [13].
Decreased storage of both produced and consumed
vitamin D may also be due to decreased levels of vitamin D
bindingprotein(DBP)inCFpatients,aphenomenonknown
to exist for 3 decades [26]. DBP shuttles vitamin D from
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Figure 2: Impaired absorption of Vitamin D following a 2500ug
dose in in CF patients and controls [13].
the intestine to fat beds. The eﬀects of low DBP on vitamin D
levels and metabolism are not entirely clear. However, most
25OHD is carried by DBP and very little is free in serum.
High concentrations of unbound DBP in normal patients
may function as a reservoir for 25OHD [27].
It is likely that CF patients have decreased vitamin D
synthesis. In the normal population, 90% to 95% of the
vitamin D requirement comes from exposure to sunlight.
Healthy individuals can obtain their vitamin D requirement
by exposing either their hands, face, and arms, or arms and
legs to sunlight. The amount needed is 2 or 3 times a week
in the spring, summer, and fall to about 20% to 25% of the
amount of sunlight it would take to cause a mild pinkness
to the skin [8, 28]. Many CF patients actively avoid sunlight
exposure due to photosensitivity from some antibiotics.
Though normal individuals store vitamin D produced in the
skin to be released during the winter, cystic ﬁbrosis patients
who are exposed to the sun may have little body fat and may
store less vitamin D, further exacerbating the problem.
4. Manifestationsof VitaminD Deﬁciency in
CF Patients
In children, severe vitamin D deﬁciency results in rickets,
but its clinical presentation in CF is more subtle. Studies
from non-CF populations show that vitamin D deﬁciency
in adults causes secondary hyperparathyroidism, resulting
in mobilization of mineral and matrix from the skeleton,
and precipitating or causing osteomalacia, but this condition
has rarely been described in CF [8]. Nonetheless, several
studies have shown abnormally high PTH levels in CF,International Journal of Endocrinology 3
Table 1: 25OH vitamin D levels in CF patients.
Ref Year Design No. of pts Mean Age Mean/MEDIAN 25OHD Level
Khazai et al. [29] 2009 RCT 30 32.3 56.8 nmol/l
Fewtrell et al. [30] 2008 observational 32 9.8 63.8
Speeckaert et al. [31] 2008 observational 116 15.1 70.9
Hillman et al. [32] 2008 RCT 15 9.1 +/− 2.3 88.75
Wolfenden et al. [33] 2008 Retrospective Cohort 185 29 ± 9 58.8
Rovner et al. [10] 2007 Prospective case/control 101 14.8 + 4.2 51.7
Gordon et al. [34] 2007 Cross sectional 64 31.4 +/− 9.1 48.4
Stephenson et al. [35] 2007 Retrospective cohort 360 28 +/− 94 7
Boyle et al. [9] 2005 Prospective tx study 134 29.6 +/− 8.9 53.7
Chavasse et al. [36] 2004 Retrospective cohort 290 9 (no SD) 65
Haworth et al. [37] 2004 RCT 30 27.7 57.5
Brown et al. [38] 2003 Case control 10 25.6 +/− 6.5 58.6
Leifke et al. [39] 2003 Cross sectional 40 27.4 +/− 5.4 39.5
Gronowitz et al. [40] 2003 Observational 70 18.8 70.2
Flohr et al. [41] 2002 Observational 75 25.3 69.3
Aris et al. [42] 2002 Case control 50 28.3 +/− 7.8 52.4
Lark et al. [13] 2001 Case control 10 28.9 +/− 8.1 49.4
Elkin et al. [43] 2001 Observational 107 28 +/− 83 8
Grey et al. [44] 2000 Cross sectional 40 10.5 +/− 3.9 74.4
Mortensen et al. [45] 2000 Case control 11 9 55
Conway et al. [46] 2000 Observational 114 24.5 44.9
Haworth et al. [47] 1999 Observational 151 25.3 +/− 7.1 47.4
Aris et al. [48] 1998 Retrospective cohort 70 28.1 52.7
Henderson and Madsen [15] 1996 Observational 54 11.0 64.9
Bhudhikanok et al. [49] 1996 Case control 49 20.6 53% were <44.9
Rochat et al. [16] 1994 Observational 12 23.3 54.9
Grey et al. [50] 1993 Observational 16 23 44.9
Stead et al. [51, 52] 1988 Observational 31 24.5 25.0
Hanly et al. [53] 1985 Observational 20 18 21.3
reduced numbers of osteoblasts on bone biopsies, and some
evidence of prolonged mineralization lag times in some CF
adults suggesting that mineralization defects, short of true
rickets/osteomalacia, do occur [54].
The complete impact of low vitamin D levels in CF
patients is yet to be determined. Though vitamin D likely has
roles in muscle function, innate immunity, cardiovascular
disease, diabetes, and some malignancies [55], there is no
information on these outcomes in CF. In fact, vitamin D has
been mainly studied in the context of CF bone disease. A
recent meta-analysis by the University of Ottawa Evidence
Based Practice Center (EPC) suggested a fair correlation
betweenlowvitaminDlevelsandBoneMassDensity(BMD)
in healthy adolescents and adults, but such correlations
have been hard to demonstrate in CF [56]. Inconsistent
correlation may also be due to a myriad of nonvitamin
D factors in CF that aﬀect bone health as well as the
known seasonal and lifetime variations in serum 25OHD
levels.
5. Role of Vitamin D Deﬁciency in
BoneHealth inCF
While the connection between low 25OHD levels and low
bone density in CF has been hard to verify, it seems highly
likely that low vitamin D levels play a role in poor bone
health that is very frequently seen in adults with CF. In
1979, 2 independent studies reported a decrease in bone
mineral content in patients with CF as compared to age-
matched controls [24, 25]. Dozens of additional reports of
low bone mass and frank osteoporosis in patients with CF,
particularlyinadolescents andadults,havebeenwrittenover
the past 30 years [15, 16, 18, 43, 46–50, 57, 58]. The US CF
Foundation 2007 Patient Registry of ∼24,000 CF individuals
reported a rate of bone disease in adults with CF of ∼21%
(along with 0.5% for bone fractures), a number which has
increased by an order of magnitude in the last 7 years largely
due to better screening and recognition of bone disease
[1].4 International Journal of Endocrinology
Despite better screening, large careful cross-sectional
studies indicate that these rates almost certainly underesti-
mate the true prevalence due to continued under-reporting.
Studies from at least 7 countries have found that low BMD
is common in both children and adults with CF, although
adultstendtobemoreaﬀected.Insomestudies,upto69%of
patientshavebeenreportedtohavelowbonemass,with57%
displaying bone density greater than 2 standard deviations
below the mean for age-matched controls [15, 16, 20, 46, 49,
50, 57, 58].
Bone mineral accrual in CF is likely inadequate [18,
54, 59], especially from late childhood through young
adulthood, when measured volumetrically by quantitative
computed tomography (QCT) [59] or when corrected for
bone volume (bone mineral apparent density (BMAD)).
Here in particular, there is a concern that inadequate vitamin
D contributes to poor bone health in CF.
Markers of bone formation and breakdown have
improved the understanding of CF bone disease, which
include the osteoblast markers bone-speciﬁc alkaline phos-
phatase and osteocalcin in addition to the osteoclast mark-
ers pyridinoline crosslinks and collagen N-telopeptides.
Thoughthesemarkersdisplaysigniﬁcantvariabilitywithage,
puberty, season, time of day, menstrual cycle, and amount
of lung infection, they support the histomorphometric
data demonstrating both increased bone breakdown and
inadequate formation [16, 21, 42, 43, 60–63]. These data,
when taken as a whole, then suggest that low BMD in CF
is a result of inadequate bone formation and increased bone
resorption, with low vitamin D as a likely contributor.
Both the degree of bone disease and degree of vitamin
D deﬁciency appear to increase with age and severity of lung
disease.Arecentstudyshowedacorrelationbetween25OHD
levels and decreased FEV1 (forced expiratory volume in
1 second, an important measure of lung function) and
nutritional status [64] .S e v e r a ls t u d i e sh a v ed e m o n s t r a t e d
positive correlation of BMD with FEV1 [15, 43, 47, 48,
59]. Increases in fracture rates may occur as early as the
late teens and early twenties, decades before increases are
seen in the general population. While increased fractures
are not solely due to vitamin D deﬁciency, this problem
does contribute. Similar to the general population, fractures
appear to occur earlier in CF women [48]. While fractures
tend to aﬀect the axillary skeleton to a greater extent than the
appendicular skeleton, no site is unaﬀected. Resultant chest
wall deformities and “splinting” due to pain from thoracic
vertebral and rib fractures can inhibit eﬀective cough and
airway clearance. Ultimately, this may accelerate the decline
in lung function in patients with CF.
Most end-stage CF patients get referred for lung trans-
plantation in developed countries. Few data are available
regarding the impact of lung transplantation on 25OHD.
One study reported that 25OHD levels went up slowly
after transplant suggesting that lung disease and systemic
ramiﬁcations of chronic inﬂammation aﬀect the absorption
of precursor molecule or the 25-hydroxylase enzyme [42].
Unfortunatelymostpatientsalreadysuﬀerfromsevereosteo-
porosis before transplant [19, 65–67] . Post lung transplant
patients carry additional fracture risk [19, 65], which may
be attributed to increased lung function and activity level.
Transplantrecipientsappeartodevelophigh-turnoverosteo-
porosis, which appears to be linked to immunosuppressants
rather than vitamin D insuﬃciency. This causes decreases
in spine and femur BMD as high as 10% in posttransplant
CF patients [19, 35, 66, 68, 69] and pathologic fracture rates
after transplant as high as 37% to 42% [66, 70]. Regardless of
the etiology, maximizing vitamin D status in the years before
transplant will likely be key to improving bone health post-
transplant.
6. Treatment of Vitamin DDeﬁciency
It is recommended that all CF patients target an optimum
25OHD level in the range of 75–150nmol/L (30–60ng/mL),
but levels up to 250nmol/L (100ng/mL) are probably still
safe. These targets are based on data outside of CF that
demonstrate that parathyroid hormone (PTH) levels (a
sensitive marker of serum ionized calcium levels) start to
rise when 25OHD levels fall below 75nmol/L (30ng/mL)
[69].
Trials have further reinforced the need to update vitamin
D supplementation algorithms. A summary of all vitamin D
related intervention research studies in the CF population
is shown in Table 2. Most early trials failed to signiﬁcantly
change participants’ serum 25OHD levels. Stephenson et al.
were able to achieve 25OHD levels ≥ 50nmol/l (20ng/mL)
in 92% of patients treated with, on average, 1800IU
D3; however only 18% of these participants reached the
ideal 75nmol/L (30ng/mL) level [35]. Gronowitz et al. had
encouraging results with the use of UVB lamps combined
with D3 supplementation, raising the mean serum 25OHD
level in this group of patients from 55nmol/L (22ng/mL)
to 125nmol/L (50ng/mL) in 12 weeks [72]. However a
recent trial by Khazai et al. saw only that 55% of patients
reach repletion levels using UVB due to diﬃculties with
compliance.Khazaiet al.alsoshowedapromisingmethodin
which100%ofparticipantstreatedwith50,000IUD3weekly
for 3 months reached the target serum 25OHD level of
>75nmol/L (30ng/mL) [29]. They also demonstrated some
success with 50,000IUD2, but to a lesser extent. Due to the
limited sample size and short duration of this study, further
research is needed in order to determine if this strategy will
be beneﬁcial for most CF patients.
The Khazai study illustrates the important point that
vitamin D2 and D3 supplementation may not be equivalent.
Non-CF patients receiving equipotent doses of D2 and
D3 had similar initial 25OHD levels, though the levels
declined more rapidly in those receiving D2 [73]. The
superiority of D3 to maintain adequate 25OHD levels has
alsobeensuggestedinearlierliteraturealthoughthisremains
controversial [73–76].
No superior supplementation strategy has been ade-
quately validated by randomized controlled trials; so current
strategies are based on expert review of available data. We
suggest a modiﬁed and updated version of a previously
published algorithm recommended by a recent consensus
conference on CF-related bone health [77], which is outlined
in Figure 3. Children younger than 1 year of age withInternational Journal of Endocrinology 5
Table 2: Vitamin D Therapy Trials in CF.
Article Design Patients Intervention Outcome Limitations
Hillman et al.
[32]
Double-
blinded
RCT
15 children aged 7–13
2000D3 + 1g Ca
versus 2000D3 versus
400D3 + 1g Ca
versus 400D3 for 6
months
No change in 25OHD,
1,25OHD levels in any arm
Short duration of
treatment, small
study, young patients
only
Boyle et al.
[9]
Open label
CT
66 adult vitamin D
deﬁcient (25OHD ≤
75nmol/L [30ng/mL])
patients
Sequential eﬀorts of
50,000 IU D2 weekly
f o r8w e e k so rt w i c e
weekly for 8 weeks
Only 5 (8%) patients
achieved repletion (25OHD
≥ 75nmol/L [30ng/mL])
Many follow up
25OHD levels may
have been drawn after
supplementation
ended.
Haworth
et al. [37]
Double-
blinded
RCT
30 adult patients with
BMD z score ≤ 1i n
lumbar spine, femur or
distal forearm
1g cal + 1700IU D3
(treatment) versus
900IUD3 (control)
over 12 months
Treatment group showed
reduced rate of bone loss,
no signiﬁcant change in
25OHD level
Small sample size,
changes in BMD not
statistically signiﬁcant
Brown et al.
[38] Open Label 10 adult CF patients10
healthy patients
5 microg calcitriol bid
for 14 days
Increased short term study
showing improved calcium
absorption in both healthy
and CF patients. In CF,
calcitriol also decreased
urine NTX in CF patients.
Short duration of
treatment, Long term
eﬀects unknown.
Calcitriol requires
close monitoring to
prevent hypecalciuria
&h y p e r c a l c e m i a
Stephenson
et al. [35]
Open Label,
dose
escalating
study
215CF adults patients
with 25OHD ≤
50nmol/L (20ng/mL)
400IUD3, 800IU D3,
1000IUD3,
>1000IUD3,
compliance
counseling
92% achieved 25OHD ≥
50nmol/L (20ng/mL) with
average dose of 1800IU/day
Only 18% of these patients
achieved 25OHD ≥
75nmol/L
No control group, no
diﬀerentiation in
outcome between
intervention arms
Khazai et al.
[29]
Open label
RCT 30 CF adult patients
50,000IU D2 weekly 100% D3 achieved 25OHD
≥ 75 nmol/L (30ng/mL) Small sample size,
limited compliance in
sun lamp arm 50,000IU D3 weekly, 60% D2 achieved 25OHD
≥ 75 nmol/L (30ng/mL)
2%–5% UVB lamps
55% sunlamps achieved
25OHD ≥ 75 nmol/L
(30ng/mL)
Green 2008
[71]
Retrospective
chart review 262 pediatric CF patients
50,000IU D2 1X
weekly, 2X weekly or
3X weekly for variable
lengths of time
33% weekly achieved
25OHD ≥ 75 nmol/L
(30ng/mL)
26% twice weekly achieved
25OHD ≥ 75 nmol/L
(30ng/mL)
43% thrice weekly 25OHD
≥ 75 nmol/L (30ng/mL)
While there was some
improvement in
levels, no treatment
was signiﬁcantly
better than controls
Gronowitz
et al. [72]
Open Label
Controlled
Trial
30 pts aged 9–40 mean
initial 25OHD
53nmol/L (21.2ng/mL)
in control and
55nmol/L (22ng/mL) in
treatment at baseline
Routine
Supplementation
(400-2250 IU D3
daily) versus Routine
Supplementation +
UVB lamps for 12
weeks
25OHD level post 8 weeks:
Control 48nmol/L
(19.2ng/mL) Intervention
110 nmol/L (44ng/mL)
Post 12 weeks: Control 63
nmol/L (25.2 ng/ml)
Intervention 125
nmol/L/mL (50ng/mL)
Limited compliance
to treatment regimen
due to skin type side
eﬀects with prolonged
UVB exposure
low 25OHD levels should receive 8000IU vitamin D per
week; individuals older than 1 year should routinely receive
800IU or more vitamin D per day. If circulating 25OHD
concentrations are still <75nmol/L (30ng/mL) and patients
are considered adherent to treatment, patients 5 years or
older may be given the Medium Dose Regimen, which we
deﬁne as 50,000IU vitamin D once per week for 12 weeks.
Patients younger than 5 years should be given 12,000IU
vitamin D once per week for 12 weeks. It is critical to recheck
the 25OHD level while on supplemental therapy and not to6 International Journal of Endocrinology
Check serum 25-OH level annually in late Fall
> 75nmol/L
< 75nmol/L
Continue previous
supplementation
Medium Dose Vitamin D for 12 Weeks:
12,000 IU/week for patients <5y e a r so l d
50,000 IU /week for patients >5y e a r so l d
Favor cholecalciferol to ergocalciferol
> 75nmol/L Recheck 25-OH Vitamin D level
< 75 nmol/L
Continue medium dose
vitamin D. Dose adjust
to keep below 200nmol/L. High Dose Vitamin D for 12 weeks:
12,000 IU biweekly for patients <5y e a r so l d
50,000 IU biweekly for patients >5y e a r so l d
Favor cholecalciferol to ergocalciferol
Recheck 25-OH Vitamin D level > 75nmol/L
< 75nmol/L
Continue High dose Vitamin D
therapy. Dose adjust to keep
below 200nmol/L.
Consider observed
phototherapy if compliant.
Verify compliance.
Figure 3: Suggested Vitamin D supplementation algorithm.
allow a lapse in the repletion eﬀort before the 25OHD level is
rechecked. All treatments requires close follow-up to ensure
that the 25OHD levels respond. Seasonal variation may need
to be accounted for in the long-term repletion eﬀort and
considerable interindividual variation in the amount needed
to achieve the goal level should be expected. Patients not
responding to the Medium Dose Regimen, after adherence
hasbeenconﬁrmed,shouldbegiventheHighDoseRegimen,
deﬁned as 50,000IU (or 12000IU for patients younger than
5 years) vitamin D biweekly and reassessment done after 12
weeks. The evolving data suggest that vitamin D amounts
in the range of 3000–5000IU/day may be needed for most
adults with CF and this amount may be dosed daily or
weekly. We currently favor vitamin D3 supplementation over
vitamin D2 until further data are available.
Some patients will have inadequate levels despite these
eﬀorts. Increased exposure to sunlight or phototherapy
without sun-blocking lotions may also be considered. Sun-
light exposure should be short enough to prevent sunburn.
Hands, face, and arms, or arms and legs should be exposed
2o r3t i m e saw e e ki nt h es p r i n g ,s u m m e r ,a n df a l lt oa n
amount of sunlight that is equivalent to about 20% to 25%
of the amount it would take to cause a mild pinkness to
the skin. Phototherapy with artiﬁcial ultraviolet lights such
as a tanning bed or portable tanning units may be used,
provided that the phototherapy unit has the component
of UV-B that is responsible for making vitamin D in the
skin. The manufacturer’s guidelines for exposure dependent
on skin type should be followed. It should be noted that
adherence to this regimen is critical, as poor compliance has
been implicated as a culprit in most negative studies.
7. FutureDirectionsinResearch
Despite our increasing knowledge about vitamin D, basic
understanding regarding the association between vitamin D
and BMD or fracture risk is still not completely clear. Studies
are needed to determine the amount of orally administered
vitamin D needed to maintain circulating concentrations of
25OHDabovethetargetlevelof>75nmol/L(30ng/mL),but
optimal dosing for clinically useful endpoints (e.g., fracture
prevention and improving/stabilizing BMD) is needed. In
all likelihood, caregivers will have to individualize doses
to some extent to meet the needs of all of their patients.
More research is needed to determine the short- and long-
term consequences of vitamin D insuﬃciency in CF. The
role of vitamin D repletion in inﬂammation in CF needs to
be explored. Vitamin D ligands (VDLs) are upregulated inInternational Journal of Endocrinology 7
inﬂammatory disease states in various cell lines, and vitamin
D’s anti-inﬂammatory role has been documented in many
diseases such as multiple sclerosis, rheumatoid arthritis, type
I and II diabetes mellitus, lupus, psoriasis, and prostate
cancer. While it is expected that ﬁndings from general
populationswithregardtolowvitaminDstatusramifytoCF
individuals, there is also concern that the anti-inﬂammatory
activity of vitamin D levels may be even more important in
CF vis a vis chronic lung infection and the systemic response
that results. Phototherapy studies are also needed to better
deﬁne the amount of exposure to UV-B radiation that is
needed to maintain 25OHD levels > 75nmol/L (30ng/mL)
without causing toxicity.
8. Conclusions
CF patients have a particularly diﬃcult time maintaining
adequate vitamin D levels for a host of environmental,
genetic, and circumstantial reasons. Added to this is a
predisposition to osteoporosis compounding the impact of
low vitamin D levels on morbidity and mortality. Physicians
caring for CF patients should be proactive in monitoring
25OHD levels with aggressive treatment of those with low
levelsinaneﬀorttopreventadverselong-termconsequences.
Consultants in endocrinology will be very helpful to CF
pulmonologists in the management of diﬃcult to treat CF
patients as their knowledge of vitamin D metabolism is
considerable. Current guidelines for repletion are similar to
those in the general population (25OHD levels > 75nmol/L
[30ng/mL]).
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